Clinical Trial Details
EORTC-40071
Back to Clinical Trials Database
Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial.
Trial Status | All trial activities ended |
---|---|
Dates |
Date of activation: 09-Dec-2010 Date Step1 close: 09-Aug-2013 |
Data management at EORTC | Yes |
Design |
Phase 2 Randomized blind |
Targeted Sample size | EORTC Groups: 192 - All Groups: 192 |
Treatment | |
Study Staff | |
Type of cancer | |
Participating groups | |
Protocol summary | http://clinicaltrials.gov/study/NCT01123473 |
NCT number | NCT01123473 |
EudraCT | 2009-011580-36 |